Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

PURPOSE: The VICTOR-1 study demonstrated that the all-oral metronomic combination of vinorelbine and capecitabine is highly active and well tolerated in hormone receptor-positive/HER2-negative patients. The VICTOR-2 study was designed to confirm these results. METHODS: Patients received mVNR 40 mg t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cazzaniga, M. E., Cortesi, L., Ferzi, A., Scaltriti, L., Cicchiello, F., Ciccarese, M., Della Torre, S., Villa, F., Giordano, M., Verusio, C., Nicolini, M., Gambaro, A. R., Zanlorenzi, L., Biraghi, E., Legramandi, L., Rulli, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090011/
https://www.ncbi.nlm.nih.gov/pubmed/27752847
http://dx.doi.org/10.1007/s10549-016-4009-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5090011/
https://www.ncbi.nlm.nih.gov/pubmed/27752847
http://dx.doi.org/10.1007/s10549-016-4009-3

Ejemplares similares